Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
Fig. 1 The structure of humanized
recombinant Fab (left) and superposition
in tube representation of two
Fabs (right).
(Robert et al. 2010)
Creative Biolabs has established the GHA® platform to germinalize humanized antibodies. Antibody humanization followed by germinalization produces human antibodies with excellent germinality index (GI). Human antibodies optimized from this platform are almost equivalent to mature human antibodies in sequence and have minimal immunogenicity, while retaining parental affinity and specificity.
Many antibody therapeutics are developed based on the humanization of antibodies raised in various species, therefore a humanized antibody usually remains a few non-human residues, especially in CDR regions which are essential for antigen recognition. However, the majority of the non-human residues in both CDR (and FR) regions are still immunogenic in humans. Also, engineered human antibodies with over 10% non-germline mutations often carry potential risks in generating more side effects; our state-of-the-art humanized antibody sequence germinalization strategies propose utmost amino acid substitutions to reduce immunogenicity yet with the affinity remained. Using in silico germinalization analyses, potential substitution residues on VL and VH (FR and CDR) will be identified and subsequently a mutant library with extensive germinalization will be constructed, combined with our unparalleled expertise in phage display library screening, the best lead candidates will be selected, purified and thoroughly characterized.
Antibodies derived from monkeys and other NHP (non-human primates) are of the most similarity in sequence to human antibodies. As a result, humanized NHP antibodies are the easiest ones to be further germinalized to have the highest germinality index (GI). For this reason, monoclonal antibodies raised in NHP (non-human primates) potentially have the lowest risk when developed into therapeutics for human use. We have strong expertise in monoclonal NHP (non-human Primates) antibody production, and we are particularly experienced in performing in-depth humanization for monoclonal antibodies raised in NHP (non-human primates). Germinalization of humanized NHP antibodies can deliver human antibodies with about 95% homology to the human germinal antibody sequences.
Other optional Human or Humanized Antibody Services:
Use the resources in our library to help you understand your options and make critical decisions for your study.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
